TherapeuticsMD (TXMD) is Suspending 2020 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
TherapeuticsMD Provides COVID-19-Related Business Update
March 26, 2020 4:05 PM EDT- Strong preliminary first quarter 2020 total net revenue projected to be more than $11 million
- vitaCare Prescription Services model allowing the Company to connect with more than 80% of patients -
- Implementing staged contingency plan that can be adjusted as COVID-19 situation evolves -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD) (TherapeuticsMD or the Company), an innovative, leading womens healthcare company, today provided an update on its operations in response to the continued spread of COVID-19 (coronavirus) pandemic. The Company has... More
